Dalbavancin Hydrochloride Patent Expiration
Dalbavancin Hydrochloride is Used for treating acute bacterial skin and skin structure infections (ABSSSI) in both adults and pediatric patients. It was first introduced by Abbvie Inc
Dalbavancin Hydrochloride Patents
Given below is the list of patents protecting Dalbavancin Hydrochloride, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Dalvance | US6900175 | Methods of administering dalbavancin for treatment of bacterial infections | May 23, 2028 | Abbvie |
| Dalvance | US7115564 | Stable pharmaceutical compositions of dalbavancin and methods of administration |
Nov 14, 2023
(Expired) | Abbvie |
| Dalvance | US7119061 | Dalbavancin compositions for treatment of bacterial infections |
Nov 14, 2023
(Expired) | Abbvie |
| Dalvance | US8143212 | Dalbavancin compositions for treatment of bacterial infections |
Nov 14, 2023
(Expired) | Abbvie |
Dalbavancin Hydrochloride's Family Patents
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List